Krystal Biotech (KRYS) logo

Krystal Biotech (KRYS) stock

Genetic medicines , market cap $9.4B

After-hours Fri
$308.85
-0.01%

Close $308.89 -2.19%

Quality Score
7
Average
In its industry
#42of 273
Checks firing
0of 14
Choppy
From 52-week high
-19.3%
under its best in a year

KRYS's Quality Score fell 2 points on Fri, Nov 20, to 7. Buying slipped from its highest in 20 days (2 chart checks stopped).

Follow KRYS's trial news. Pro members can get an alert when Krystal Biotech files news, and see its trials, share raises, and its CEO's filings.

Get an alert when KRYS files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“The Company expects to report interim study results before the end of the year.”Trial data · SEC filing · Nov 2

Why KRYS rose 4% since Nov 16

Up 4% from Nov 16 to Nov 20 while the S&P 500 fell 7%.

  • Krystal Biotech rose 4% from Nov 16 to Nov 20. It rose 6% on Nov 18 alone.

Sources: Price history, Nov 20, 2026

1 more reason, free with an account →See every reason on KRYS →The other side, the timeline, and its peers, for Pro members.

Key facts on KRYS

Key facts on KRYS
The companySales up 26% on the year
Latest filing8-K, Nov 2 Reported its quarterly results

What's next

Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Expected to report Tue Feb 16, before the open

After its last 4 reports it closed -1.8% on average, higher 2 of 4 times.

1 more date ahead: the conference, for Pro members.

KRYS catalysts

Coming up

9 more coming up and 8 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for KRYS

Next step the company has named

End of 2026“The Company expects to report interim study results before the end of the year.”Trial data · SEC filing · Nov 2

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
IOLITEPhase 3 · Recruiting · 16 people · main data estimated Dec 2026 · NCT07016750

8 more trials, 3 with data due this year, 7 more milestones and 33 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

President, R&D Suma Krishnan sold 25,000 shares on Sep 4, under a planned sale. 13 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Krish Krishnan’s 12 filings and quotes.

Get an alert when KRYS files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why KRYS scores 7

Averagefor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means

  • +2Long-term trend above a rising 200-⁠day average
  • +3Growth sales up 26% on the year, operating margin up 6.0 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Persistence adds

No effect today: Chart checks, Run-up, Size, Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on KRYS and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:39 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when KRYS's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How KRYS ranks in Biotech

KRYS is #42 of 273 by Quality Score.

How KRYS ranks in Biotech
RankStockQuality Score
42Krystal Biotech (KRYS) logoKRYSKrystal Biotech7

Share count against a year before: KRYS +2.3%, TARS +9%, CRSP +6%, MRNA +2.8%.

More in Biotech

When does KRYS report earnings, and what happens after?

Expected to report Tue Feb 16, before the open (in 87 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What KRYS reported on Nov 2, 2026

The quarter

A profit of $2.05 a share, from $2.66.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

KRYS's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$9.4B
today
Sales
$470M
up 26% on the year
Free cash flow
$310M
last 12 months

Its share count grew 5.5% a year over 3 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on KRYS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+7.9%-8.4%-10.9%
May 4Aug 3Nov 2
ReportedGapReaction5
days
Nov 2, 2026Before open-5.4%-10.9%-9.4%
Aug 3, 2026Before open-6.0%-8.4%-4.3%
May 4, 2026Before open-0.2%+7.9%+14.9%

KRYS closed higher after 2 of its last 4 reports.

All 4 reports, and KRYS's Quality Score going into each

KRYS sales and profit by year

Sales and profit by year

Sales grew in three of the last four years, to $389M in 2025. It made a profit in three of the five years.

Nothing is firing on KRYS right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on KRYS, and all 14 on every stock.Get in free →See the top 3 →Start Pro

KRYS RSI on Nov 20: 47.3, below its 50-day and 200-day averages

Not scored

RSI 47.3, MACD above signal, below both averages. Not scored.

The deep dive on KRYS

7 more findings on KRYS, each with its source, for Pro members.

KRYS insider trades

One insider sold $8.2M across 8 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellDino A. Rossi$2.4MDirectorat $329.60 on Aug 14, filed Aug 14

All 8 insider filings on KRYS from the last six months, for Pro members.

All KRYS insider trades

KRYS trades by Congress and the executive branch

4 trades disclosed in the last six months. The newest:

SellDonald Trump$1K to $15KPresident (R)traded Sep 10, disclosed Nov 19(70 days later)
All 4 trades on KRYS disclosed by Congress and the executive branch, for Pro members.Get in free →See the top 3 →Start Pro

See what Congress is buying across the market

KRYS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold KRYS?

In ETFs: KRYS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Krystal Biotech

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

295 employeesPittsburgh, PAkrystalbio.com

What Krystal Biotech says it competes with

“The biotechnology and pharmaceutical industries are highly competitive.”

From its annual report, SEC filing · Feb 17, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on KRYS and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move KRYS's score: 5 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayAug 22Donald Trump bought KRYS$1K to $15K, disclosed Aug 22

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: KRYS's Quality Score is 7 (Average), #42 of 273 in Biotech. Insiders sold $8.2M in the last 6 months (Form 4).

What does KRYS's Quality Score say?

KRYS scores 7 today, which Breakaway calls Average. It is #42 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Up 4% from Nov 16 to Nov 20 while the S&P 500 fell 7%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is KRYS's Quality Score?

KRYS scores 7 today, which Breakaway calls Average (6 to 10). That is #42 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KRYS's 7.

Are insiders buying KRYS?

One insider sold $8.2M across 8 filings in the last 6 months. No open-⁠market buys on record. The newest is Dino A. Rossi, Director, who sold $2.4M on Aug 14. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Krystal Biotech: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.